Dario Alessi focuses on unravelling the roles played by components that regulate protein modification pathways in human disease. He has contributed to our understanding of several disease-relevant signal transduction pathways, including PDK1 (involved in diabetes and cancer), LKB1 (cancer) and WNKs (blood pressure regulation). Much of his current work is centered on understanding how mutations in LRRK2 cause Parkinson’s disease. Dr. Alessi serves as the director of the MRC Protein Phosphorylation and Ubiquitylation Unit, where researchers work with industry and clinicians to better understand the diseases that result from disruption of signaling networks.
He also serves as director of the Dundee Signal Transduction Therapy Unit, a collaboration between scientists at the University of Dundee and pharmaceutical companies that is dedicated to accelerating the development of inhibitors and chemical probes that target protein modification systems for the treatment of disease and the study of cell signaling.
Dr. Alessi earned BSc and PhD degrees at the University of Birmingham (UK); he completed postdoctoral training at the University of Dundee. He is a fellow of the UK Royal Society and Academy of Medical Sciences.